NewAmsterdam Pharma Stock (NASDAQ:NAMS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$23.60

52W Range

$14.06 - $27.29

50D Avg

$19.90

200D Avg

$20.73

Market Cap

$2.63B

Avg Vol (3M)

$855.37K

Beta

-0.03

Div Yield

-

NAMS Company Profile


NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

NL

Employees

68

IPO Date

Feb 09, 2021

Website

NAMS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22
License Revenue$93.50M

Fiscal year ends in Dec 24 | Currency in USD

NAMS Financial Summary


Dec 24Dec 23Dec 22
Revenue$45.56M$12.76M$95.91M
Operating Income$-176.29M$-165.73M$-3.32M
Net Income-$-176.94M$-21.14M
EBITDA-$-176.86M$-3.31M
Basic EPS$-2.56$-2.15$-1.11
Diluted EPS$-2.56$-2.15$-1.11

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
STROSutro Biopharma, Inc.
TYRATyra Biosciences, Inc.
NUVLNuvalent, Inc.
HLVXHilleVax, Inc.
PROKProKidney Corp.
CNTACentessa Pharmaceuticals plc
PEPGPepGen Inc.